Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 73,192 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock in a transaction on Friday, October 31st. The stock was sold at an average price of $1.28, for a total transaction of $93,685.76. Following the transaction, the director directly owned 4,003,728 shares of the company’s stock, valued at $5,124,771.84. The trade was a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Luke Evnin also recently made the following trade(s):

• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $77,876.01.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total transaction of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total transaction of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $80,262.08.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $1.31 on Tuesday. The firm has a market capitalization of $59.91 million, a P/E ratio of -0.80 and a beta of 0.73. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.52. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. The firm has a fifty day moving average price of $1.62 and a 200-day moving average price of $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

HOWL has been the topic of several recent analyst reports. Bank of America cut their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics during the 1st quarter worth $34,000. Charles Schwab Investment Management Inc. boosted its stake in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the last quarter. Nuveen LLC acquired a new stake in Werewolf Therapeutics during the 1st quarter worth $71,000. MPM Asset Management LLC boosted its stake in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Finally, MPM Bioimpact LLC boosted its stake in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.